News Headlines

  1. BBG Advanced Therapies And CELLforCURE Partner To Provide Transatlantic Manufacturing Solutions For Advanced Therapy Medicinal Products (ATMPs) 10/8/2025

    BBG Advanced Therapies, a subsidiary of BioBridge Global (San Antonio, Texas, USA), and CELLforCURE, part of SEQENS Group, (Les Ulis, France) are proud to announce a partnership dedicated to supporting the development and large-scale production of Advanced Therapy Medicinal Products (ATMPs).

  2. Celonic Group And CARBOGEN AMCIS Announce Strategic Alliance To Deliver Fully Integrated ADC Development And Manufacturing Platform 10/7/2025

    Celonic Group one of the leading “pureplay” Biologics CDMO, and The Carbogen Amcis Group, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, today announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution.

  3. OXB Expands US Footprint With Acquisition Of Commercial-Scale Viral Vector Facility In North Carolina 10/7/2025

    OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has signed and closed an asset purchase transaction to acquire a custom-built, state-of-the-art cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc. (Resilience).

  4. Scinai Awarded Israel Innovation Authority Grant To Expand Fill-And-Finish CDMO Capabilities 10/6/2025

    Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai Bioservices, today announced that it has been awarded a non-dilutive grant of approximately NIS 809,000 (about $246,000) from the Israel Innovation Authority (IIA).

  5. Made Scientific And Streamline Bio Announce Collaboration To Accelerate AI-Driven Robotic Manufacturing For Cell Therapies 10/6/2025

    Made Scientific, a leading clinical and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company solving critical challenges in cell and gene therapy (CGT) manufacturing processes, today announced successful initial validation of Streamline Bio's AI-driven precision robotics platform in a live cell therapy production environment.

  6. Kincell Bio Announces Strategic Collaboration With Major Academic Medical Center To Advance Cell And Gene Therapy Innovation 10/6/2025

    Kincell Bio Inc., a cell therapy contract development and manufacturing organization, today announced the signing of a memorandum of understanding with the Duke University School of Medicine.

  7. Mytos Launches Automated CDMO For Scalable, Low-Cost Manufacturing Of Stem-Cell Derived Therapies 10/6/2025

    Mytos, a biotechnology company automating cell manufacturing, today announced the launch of its automated contract development and manufacturing organization (CDMO) offering, to overcome one of regenerative medicine’s greatest bottlenecks: scalable, affordable manufacturing of stem cell-derived therapies.

  8. Lonza Expands Its TheraPEAK Product Portfolio With The Addition Of AmpliCell Cytokine Range And TheraPEAK 293-GT Medium 10/6/2025

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium to expand its GMP solutions for cell and gene therapy.

  9. Execution Of Agreements Regarding The Joint Development Of Biosimilars For Specified Products 10/6/2025

    Alfresa Holdings Corporation (head office: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter “Alfresa Holdings”); Kidswell Bio Corporation (head office: Chuo-ku, Tokyo; President & CEO: Shinya Kurebayashi; hereinafter “Kidswell”); and Chiome Bioscience Inc. (head office: Shibuya-ku, Tokyo; President & CEO: Masamichi Koike; hereinafter “Chiome”) have entered into agreements regarding the joint development of biosimilars*1 for specified products (hereinafter referred to as the “Agreement”).

  10. Rentschler Biopharma Further Expands Its Services In Japan And South Korea And Will Attend Bioprocess International Asia 10/6/2025

    Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is highlighting its flexible and optimized solutions for the development and manufacture of a wide range of biologics for clients in Japan and South Korea.